-
1
-
-
34547145776
-
-
Merriam-Webster Online Dictionary. www.m-w.com/dictionary/pain (accessed 2006 Aug 1).
-
Merriam-Webster Online Dictionary. www.m-w.com/dictionary/pain (accessed 2006 Aug 1).
-
-
-
-
2
-
-
0016227011
-
A historical-phenomenological study of bodily pain in Western man
-
De Moulin D. A historical-phenomenological study of bodily pain in Western man. Bull Hist Med 1974;48:540-69.
-
(1974)
Bull Hist Med
, vol.48
, pp. 540-569
-
-
De Moulin, D.1
-
3
-
-
34547172229
-
-
Milton J. Paradise lost. New York: Norton WW & Company, Inc., 2004 (original 1666).
-
Milton J. Paradise lost. New York: Norton WW & Company, Inc., 2004 (original 1666).
-
-
-
-
5
-
-
0022523784
-
Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms
-
International Association for the Study of Pain
-
International Association for the Study of Pain. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Pain 1986;3(suppl):S1-225.
-
(1986)
Pain
, vol.3
, Issue.SUPPL.
-
-
-
6
-
-
0003882050
-
Cancer pain relief and palliative care
-
World Health Organization, Committee, 3rd ed. WHO: Geneva
-
World Health Organization. Cancer pain relief and palliative care: Report of WHO Expert Committee, 3rd ed. WHO: Geneva, 1996.
-
(1996)
Report of WHO Expert
-
-
-
7
-
-
34547186627
-
: Endogenous opioids
-
Warfield CA, Fausett HJ, eds, 2nd ed. New York: Lippincott Williams & Wilkins
-
Stranc DS. Chapter 3: endogenous opioids. In: Warfield CA, Fausett HJ, eds. Manual of pain management. 2nd ed. New York: Lippincott Williams & Wilkins, 2002.
-
(2002)
Manual of pain management
-
-
Stranc, D.S.1
-
8
-
-
34547146430
-
-
FDA OKs the pain drug Opana: prescription drug is oral form of painkiller that used to be injection-only. WebMD. www.webmd.com/content/article/124/ 115549.htm (accessed 2006 Aug 1).
-
FDA OKs the pain drug Opana: prescription drug is oral form of painkiller that used to be injection-only. WebMD. www.webmd.com/content/article/124/ 115549.htm (accessed 2006 Aug 1).
-
-
-
-
9
-
-
12144289451
-
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydromorphone]
-
Ananthan S, Khare NK, Saini SK, et al. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydromorphone]. J Med Chem 2004;47:1400-12.
-
(2004)
J Med Chem
, vol.47
, pp. 1400-1412
-
-
Ananthan, S.1
Khare, N.K.2
Saini, S.K.3
-
10
-
-
34547155210
-
-
Package insert. Opana oxymorphone hydrochloride, Chadds Ford, PA: Endo Pharmaceuticals Inc, Jun 2006
-
Package insert. Opana (oxymorphone hydrochloride). Chadds Ford, PA: Endo Pharmaceuticals Inc, Jun 2006.
-
-
-
-
11
-
-
34547162959
-
-
Package insert. Opana ER oxymorphone hydrochloride extended-release, Chadds Ford, PA: Endo Pharmaceuticals Inc, June 2006
-
Package insert. Opana ER (oxymorphone hydrochloride extended-release). Chadds Ford, PA: Endo Pharmaceuticals Inc, June 2006.
-
-
-
-
13
-
-
1842480273
-
Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: Results of a randomized crossover study
-
Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 2004;24:468-76.
-
(2004)
Pharmacotherapy
, vol.24
, pp. 468-476
-
-
Adams, M.P.1
Ahdieh, H.2
-
14
-
-
0037369176
-
Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, part I
-
Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003;44:167-71.
-
(2003)
Psychosomatics
, vol.44
, pp. 167-171
-
-
Armstrong, S.C.1
Cozza, K.L.2
-
15
-
-
16844377997
-
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
-
Adams M, Pieniaszek HJ. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 2005; 45:337-45.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 337-345
-
-
Adams, M.1
Pieniaszek, H.J.2
-
16
-
-
28844473848
-
Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: Results of a randomized, double-blind, placebo-controlled trial
-
Gimbel JS, Walker D, Ma T, Ahdieh H. Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2005;86:2284-9.
-
(2005)
Arch Phys Med Rehabil
, vol.86
, pp. 2284-2289
-
-
Gimbel, J.S.1
Walker, D.2
Ma, T.3
Ahdieh, H.4
-
17
-
-
13244272132
-
Effectiveness and safety of oral extended release oxymorphone for the treatment of cancer pain: A pilot study
-
Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 2005;13:57-65.
-
(2005)
Support Care Cancer
, vol.13
, pp. 57-65
-
-
Sloan, P.1
Slatkin, N.2
Ahdieh, H.3
-
18
-
-
28444472350
-
Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled Phase III trial
-
Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled Phase III trial. Pain Med 2005;6:357-66.
-
(2005)
Pain Med
, vol.6
, pp. 357-366
-
-
Matsumoto, A.K.1
Babul, N.2
Ahdieh, H.3
-
19
-
-
2942640367
-
Efficacy of oxymorphone extended release in postsurgical pain: A randomized clinical trial in knee arthroplasty
-
Ahdieh H, Ma T, Babul N, Lee D. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. J Clin Pharmacol 2004;44:767-76.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 767-776
-
-
Ahdieh, H.1
Ma, T.2
Babul, N.3
Lee, D.4
-
20
-
-
17144390270
-
Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A one-year study
-
McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther 2005;12:106-12.
-
(2005)
Am J Ther
, vol.12
, pp. 106-112
-
-
McIlwain, H.1
Ahdieh, H.2
-
21
-
-
6444221477
-
The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain
-
Gimbel J, Ahdieh H. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 2004;99:1472-7.
-
(2004)
Anesth Analg
, vol.99
, pp. 1472-1477
-
-
Gimbel, J.1
Ahdieh, H.2
-
22
-
-
0037626715
-
-
Oxymorphone-Endo/Penwest: EN 3202, EN 3203. Drugs R D 2003;4: 204-6.
-
Oxymorphone-Endo/Penwest: EN 3202, EN 3203. Drugs R D 2003;4: 204-6.
-
-
-
-
23
-
-
84858086550
-
Penwest. Patterson, NY. Gamma scintigraphy imaging and pharmacokinetic analysis of extended release TIMERx technology (abstract 831)
-
Presented at:, Vancouver, BC, Canada, May 6-9, accessed Jul 26
-
Baichwal A, Staniforth J, Adams M, Ahdieh H. Penwest. Patterson, NY. Gamma scintigraphy imaging and pharmacokinetic analysis of extended release TIMERx technology (abstract 831). Presented at: American Pain Society Annual Meeting, Vancouver, BC, Canada, May 6-9, 2004. www.ampainsoc.org/db2/abstract/ view?poster_id=2123#831 (accessed 2006 Jul 26).
-
(2004)
American Pain Society Annual Meeting
-
-
Baichwal, A.1
Staniforth, J.2
Adams, M.3
Ahdieh, H.4
-
24
-
-
84858099956
-
-
Penwest Pharmaceuticals Co, accessed 2006 Aug 3
-
Penwest Pharmaceuticals Co. 2006. www.penwest.com/timerx_description. html (accessed 2006 Aug 3).
-
(2006)
-
-
-
25
-
-
32444442890
-
Psychostimulants and delirium in patients receiving palliative care
-
Keen JC, Brown D. Psychostimulants and delirium in patients receiving palliative care. Palliat Support Care 2004;2:199-202.
-
(2004)
Palliat Support Care
, vol.2
, pp. 199-202
-
-
Keen, J.C.1
Brown, D.2
-
26
-
-
2642540605
-
-
National Pharmaceutical Council (NPC) and Joint Commission on Accreditation of Healthcare Organizations JCAHO
-
Berry PH, Chapman CR, Covington EC, Dahl JL, Katz JA, Miaskowski C. Pain: current understanding of assessment, management, and treatments. National Pharmaceutical Council (NPC) and Joint Commission on Accreditation of Healthcare Organizations (JCAHO) 2001.
-
(2001)
Pain: Current understanding of assessment, management, and treatments
-
-
Berry, P.H.1
Chapman, C.R.2
Covington, E.C.3
Dahl, J.L.4
Katz, J.A.5
Miaskowski, C.6
-
27
-
-
0034897861
-
Equianalgesic dose ratios for opioids
-
Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. J Pain Symptom Manage 2001;22:672-87.
-
(2001)
J Pain Symptom Manage
, vol.22
, pp. 672-687
-
-
Pereira, J.1
Lawlor, P.2
Vigano, A.3
Dorgan, M.4
Bruera, E.5
-
28
-
-
34547182931
-
-
Package insert. MS Contin morphine sulfate controlled-release, Stamford, CT: Purdue Pharma LP, Jun 2005
-
Package insert. MS Contin (morphine sulfate controlled-release). Stamford, CT: Purdue Pharma LP, Jun 2005.
-
-
-
-
29
-
-
3042595723
-
Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study
-
Jun 1;
-
Gabrail N, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004 Jun 1;20:911-8.
-
(2004)
Curr Med Res Opin
, vol.20
, pp. 911-918
-
-
Gabrail, N.1
Dvergsten, C.2
Ahdieh, H.3
|